Association between serum LDH and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma

To the Editor: Immune checkpoint inhibitors (ICIs) represent a major breakthrough in the treatment of advanced malignancies. Although prior studies have sought to identify predictive biomarkers for ICI treatment response and the development of immune-related adverse events (irAEs),1 there is limited research regarding the relationship between clinical biomarkers such as tumor burden and cutaneous immune-related adverse events (cirAEs), which are among the most prevalent irAEs.2 We thus evaluated the association between cirAE incidence or severity and tumor burden using serum lactate dehydrogenase (LDH)3 as a surrogate marker.